The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended to extend market exclusivity and block generic rivals.
For the last few years, Walmart has been promising to disrupt the US healthcare sector with a national network of clinics providing low-cost care and telehealth services.
California has said it will start selling its own generic version of overdose reversal agent naloxone in another example of the use of government-level purchasing power to
In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson
Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA.
Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommenda
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.